Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher

By: Dylan Sikes – AllPennyStocks.com News

Monday, June 17, 2024

Imagine a new weapon in the fight against cancer, a personalized therapy that utilizes the body's own immune system to attack tumors. Science fiction? This biotech company just secured exclusive rights to such technology, and its existing trials are already underway.

Biopharma company Northwest Biotherapeutics, Inc. (OTCQB: NWBO) announced in a press release today that it has licensed promising new technology from Roswell Park Comprehensive Cancer Center to develop personalized cancer treatments. These improved dendritic cell therapies are already in early testing (Phase 2 trials) for multiple cancers, and NW Bio plans to collaborate with the lead scientist on further development.

Northwest Biotherapeutics is a development-stage American pharmaceutical company headquartered in Maryland, focusing on developing immunotherapies against different types of cancer. Given the company’s infrastructure, systems and experience in producing and delivering personalized living-cell DC-based therapies for large numbers of patients, it is in a unique position to help accelerate the late-stage development of the licensed DC technologies.

Shares of the biopharma firm were trading higher in heavy morning trade.

Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.